Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA enforcement declines – House report

This article was originally published in The Tan Sheet

Executive Summary

FDA enforcement of food and drug laws declined "dramatically" between 2000 and 2005, and FDA officials "routinely reject the enforcement recommendations of career field staff," according to a report released by the Democratic staff of the House Government Reform Committee June 26. The report was requested by Rep. Henry Waxman (D-Calif.). The number of warning letters sent by the agency for violations decreased in all FDA centers by an average of over 50%, from 1,154 issued in 2000 to 535 in 2005, the report states. Warning letters for the Center for Food Safety & Applied Nutrition declined 45%. Additionally, the number of products seized by the agency for being defective, mislabeled or dangerous dropped 44%, the study finds. The decrease in enforcement actions does not indicate a reduction in violations; the number of violations reported by FDA field agents has remained relatively constant, the report maintains. Waxman, CSPI and Public Citizen held a joint news conference on FDA's "failings" June 27....

You may also be interested in...



Fewer Warning Letters: Does Change Point To FDA Advancement Or Decline?

A growing preference for voluntary compliance from drug firms is one contributor to the "steady decrease in the number of CDER warning letters," according to FDAer Robert Maffei

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

PS099515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel